Physician profile
Daniel Dunker
NPI 1407809544
$4,045.81
in general payments reported to CMS, 2019-2025
27 companies · $179 in 2025
The $179 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,943 · 2020: $257 · 2021: $74.30 · 2022: $172 · 2023: $309 · 2024: $113 · 2025: $179.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $601.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $600.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $2,365.39 | 2019-2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $196.56 | 2024-2025 | Lifevest |
| Astrazeneca Pharmaceuticals Lp | $177.01 | 2019-2020 | |
| Edwards Lifesciences Corporation | $135.81 | 2019-2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Angiodynamics, INC. | $130.69 | 2023 | Angiovac |
| Chiesi USA, INC. | $120.46 | 2021-2022 | |
| Terumo Medical Corporation | $107.04 | 2023 | Glidewire |
| Pfizer INC. | $91.27 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $75.56 | 2019-2022 | |
| Amgen INC. | $68.25 | 2019-2020 | |
| Biotronik INC. | $66.72 | 2019-2025 | Amvia Edge |
| Boston Scientific Corporation | $65.76 | 2019-2022 | |
| Amarin Pharma, INC. | $64.41 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $58.11 | 2019-2020 | |
| Lundbeck LLC | $36.43 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $34.57 | 2019 | |
| Merck Sharp & Dohme LLC | $31.99 | 2023 | Verquvo |
| Janssen Biotech, INC. | $30.52 | 2022 | |
| Janssen Pharmaceuticals, INC | $27.74 | 2019-2020 | |
| Astellas Pharma US INC | $24.10 | 2019 | |
| Abbott Laboratories | $23.93 | 2019 | |
| Abiomed | $23.54 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.48 | 2024 | Jardiance |
| Cardiovascular Systems INC. | $23.14 | 2020-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.70 | 2023 | |
| Aegerion Pharmaceuticals, INC. | $14.26 | 2019 | |
| Medtronic, INC. | $12.37 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Dunker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.